批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期 | 提交号 | 审批结论 | 申请内容分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2024/03/14 |
SUPPL-22(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2022/11/09 |
SUPPL-20(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2020/09/25 |
SUPPL-18(补充) |
Approval |
Labeling |
901 REQUIRED
|
|
|
2019/10/18 |
SUPPL-17(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2019/05/16 |
SUPPL-15(补充) |
Approval |
Efficacy |
PRIORITY
|
|
|
2016/11/18 |
SUPPL-11(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
2015/04/21 |
SUPPL-13(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2013/10/16 |
SUPPL-12(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2012/10/31 |
SUPPL-10(补充) |
Approval |
Labeling |
901 REQUIRED
|
|
|
2012/02/28 |
SUPPL-9(补充) |
Approval |
Labeling |
UNKNOWN
|
|
|
2012/02/28 |
SUPPL-8(补充) |
Approval |
Labeling |
UNKNOWN
|
|
|
2011/08/03 |
SUPPL-6(补充) |
Approval |
Labeling |
UNKNOWN
|
|
|
2011/06/16 |
SUPPL-5(补充) |
Approval |
Labeling |
UNKNOWN
|
|
|
2010/06/01 |
SUPPL-2(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2009/08/03 |
ORIG-1(原始申请) |
Approval |
Type 1 - New Molecular Entity |
STANDARD
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
与本品治疗等效的药品
活性成分:PITAVASTATIN CALCIUM 剂型/给药途径:TABLET;ORAL 规格:EQ 1MG BASE 治疗等效代码:AB
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
022363 |
001 |
NDA |
LIVALO |
PITAVASTATIN CALCIUM |
TABLET;ORAL |
EQ 1MG BASE |
Prescription |
Yes |
No |
AB |
2009/08/03
|
KOWA CO |
206015 |
001 |
ANDA |
PITAVASTATIN CALCIUM |
PITAVASTATIN CALCIUM |
TABLET;ORAL |
EQ 1MG BASE |
Prescription |
No |
No |
AB |
2016/12/20
|
AUROBINDO PHARMA |
205932 |
001 |
ANDA |
PITAVASTATIN CALCIUM |
PITAVASTATIN CALCIUM |
TABLET;ORAL |
EQ 1MG BASE |
Prescription |
No |
No |
AB |
2017/02/03
|
ORIENT PHARMA CO LTD |
205955 |
001 |
ANDA |
PITAVASTATIN CALCIUM |
PITAVASTATIN CALCIUM |
TABLET;ORAL |
EQ 1MG BASE |
Prescription |
No |
No |
AB |
2017/02/03
|
SAWAI USA |
206070 |
001 |
ANDA |
PITAVASTATIN CALCIUM |
PITAVASTATIN CALCIUM |
TABLET;ORAL |
EQ 1MG BASE |
Prescription |
No |
No |
AB |
2019/04/04
|
MYLAN |
206047 |
001 |
ANDA |
PITAVASTATIN CALCIUM |
PITAVASTATIN CALCIUM |
TABLET;ORAL |
EQ 1MG BASE |
Prescription |
No |
No |
AB |
2023/02/22
|
ZYDUS PHARMS |
206029 |
001 |
ANDA |
PITAVASTATIN CALCIUM |
PITAVASTATIN CALCIUM |
TABLET;ORAL |
EQ 1MG BASE |
Prescription |
No |
No |
AB |
2023/11/20
|
LUPIN LTD |
205977 |
001 |
ANDA |
PITAVASTATIN CALCIUM |
PITAVASTATIN CALCIUM |
TABLET;ORAL |
EQ 1MG BASE |
Prescription |
No |
No |
AB |
2024/04/30
|
HETERO LABS LTD V |
205961 |
001 |
ANDA |
PITAVASTATIN CALCIUM |
PITAVASTATIN CALCIUM |
TABLET;ORAL |
EQ 1MG BASE |
Prescription |
No |
No |
AB |
2024/08/20
|
AMNEAL PHARMS NY |
活性成分:PITAVASTATIN CALCIUM 剂型/给药途径:TABLET;ORAL 规格:EQ 2MG BASE 治疗等效代码:AB
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
022363 |
002 |
NDA |
LIVALO |
PITAVASTATIN CALCIUM |
TABLET;ORAL |
EQ 2MG BASE |
Prescription |
Yes |
No |
AB |
2009/08/03
|
KOWA CO |
206015 |
002 |
ANDA |
PITAVASTATIN CALCIUM |
PITAVASTATIN CALCIUM |
TABLET;ORAL |
EQ 2MG BASE |
Prescription |
No |
No |
AB |
2016/12/20
|
AUROBINDO PHARMA |
205932 |
002 |
ANDA |
PITAVASTATIN CALCIUM |
PITAVASTATIN CALCIUM |
TABLET;ORAL |
EQ 2MG BASE |
Prescription |
No |
No |
AB |
2017/02/03
|
ORIENT PHARMA CO LTD |
205955 |
002 |
ANDA |
PITAVASTATIN CALCIUM |
PITAVASTATIN CALCIUM |
TABLET;ORAL |
EQ 2MG BASE |
Prescription |
No |
No |
AB |
2017/02/03
|
SAWAI USA |
206070 |
002 |
ANDA |
PITAVASTATIN CALCIUM |
PITAVASTATIN CALCIUM |
TABLET;ORAL |
EQ 2MG BASE |
Prescription |
No |
No |
AB |
2019/04/04
|
MYLAN |
206047 |
002 |
ANDA |
PITAVASTATIN CALCIUM |
PITAVASTATIN CALCIUM |
TABLET;ORAL |
EQ 2MG BASE |
Prescription |
No |
No |
AB |
2023/02/22
|
ZYDUS PHARMS |
206029 |
002 |
ANDA |
PITAVASTATIN CALCIUM |
PITAVASTATIN CALCIUM |
TABLET;ORAL |
EQ 2MG BASE |
Prescription |
No |
No |
AB |
2023/11/20
|
LUPIN LTD |
205977 |
002 |
ANDA |
PITAVASTATIN CALCIUM |
PITAVASTATIN CALCIUM |
TABLET;ORAL |
EQ 2MG BASE |
Prescription |
No |
No |
AB |
2024/04/30
|
HETERO LABS LTD V |
205961 |
002 |
ANDA |
PITAVASTATIN CALCIUM |
PITAVASTATIN CALCIUM |
TABLET;ORAL |
EQ 2MG BASE |
Prescription |
No |
No |
AB |
2024/08/20
|
AMNEAL PHARMS NY |
活性成分:PITAVASTATIN CALCIUM 剂型/给药途径:TABLET;ORAL 规格:EQ 4MG BASE 治疗等效代码:AB
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
022363 |
003 |
NDA |
LIVALO |
PITAVASTATIN CALCIUM |
TABLET;ORAL |
EQ 4MG BASE |
Prescription |
Yes |
Yes |
AB |
2009/08/03
|
KOWA CO |
206015 |
003 |
ANDA |
PITAVASTATIN CALCIUM |
PITAVASTATIN CALCIUM |
TABLET;ORAL |
EQ 4MG BASE |
Prescription |
No |
No |
AB |
2016/12/20
|
AUROBINDO PHARMA |
205932 |
003 |
ANDA |
PITAVASTATIN CALCIUM |
PITAVASTATIN CALCIUM |
TABLET;ORAL |
EQ 4MG BASE |
Prescription |
No |
No |
AB |
2017/02/03
|
ORIENT PHARMA CO LTD |
205955 |
003 |
ANDA |
PITAVASTATIN CALCIUM |
PITAVASTATIN CALCIUM |
TABLET;ORAL |
EQ 4MG BASE |
Prescription |
No |
No |
AB |
2017/02/03
|
SAWAI USA |
206070 |
003 |
ANDA |
PITAVASTATIN CALCIUM |
PITAVASTATIN CALCIUM |
TABLET;ORAL |
EQ 4MG BASE |
Prescription |
No |
No |
AB |
2019/04/04
|
MYLAN |
206047 |
003 |
ANDA |
PITAVASTATIN CALCIUM |
PITAVASTATIN CALCIUM |
TABLET;ORAL |
EQ 4MG BASE |
Prescription |
No |
No |
AB |
2023/02/22
|
ZYDUS PHARMS |
206029 |
003 |
ANDA |
PITAVASTATIN CALCIUM |
PITAVASTATIN CALCIUM |
TABLET;ORAL |
EQ 4MG BASE |
Prescription |
No |
No |
AB |
2023/11/20
|
LUPIN LTD |
205977 |
003 |
ANDA |
PITAVASTATIN CALCIUM |
PITAVASTATIN CALCIUM |
TABLET;ORAL |
EQ 4MG BASE |
Prescription |
No |
No |
AB |
2024/04/30
|
HETERO LABS LTD V |
205961 |
003 |
ANDA |
PITAVASTATIN CALCIUM |
PITAVASTATIN CALCIUM |
TABLET;ORAL |
EQ 4MG BASE |
Prescription |
No |
No |
AB |
2024/08/20
|
AMNEAL PHARMS NY |